BioWorld - Saturday, April 11, 2026

Diabetes
Diabetes RSS Feed RSS

Handshake with DNA, molecules
Endocrine/Metabolic

Genprex enters license agreement with University of Pittsburgh to support diabetes program

Dec. 16, 2022
Genprex Inc. has entered into a license agreement with the University of Pittsburgh designed to strengthen its diabetes program. The agreement grants Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, nonexclusive license to use certain related know-how, all related to modulating autoimmunity in type 1 diabetes by using gene therapy.
Read More
Endocrine/Metabolic

TLC-6740 demonstrates multiple metabolic benefits in vivo

Nov. 22, 2022
Scientists from Orsobio Inc. and affiliated organizations have described preclinical data for the novel liver-targeted mitochondrial protonophore TLC-6740, being developed for the treatment of metabolic disease. In vitro, mild mitochondrial uncoupling caused by TLC-6740 had pleotropic metabolic benefits in multiple cell lines. TLC-6740 increased mitochondrial potential, oxygen consumption rate and tricarboxylic acid (TCA) cycle flux, and it also inhibited de novo lipogenesis with EC50 values of 6.9 µM.
Read More
Oral medication

NMPA nod gives Hua Medicine first GKA approval in diabetes

Oct. 11, 2022
By Doris Yu
Hua Medicine Ltd. has received marketing approval from China's NMPA for its glucokinase activator (GKA), Huatangning (dorzagliatin tablets), for two indications: as a monotherapy to improve blood glucose control for drug-naïve type 2 diabetes patients and in combination with metformin in metformin-tolerated type 2 diabetes patients to control blood glucose level. It marks the first GKA drug to gain approval in any market, according to Hua.
Read More
Light micrograph and 3D illustration of small intestine villi
Drug Design, Drug Delivery & Technologies

Robocap, a mucus-clearing capsule to enhance drug delivery into the gastrointestinal tract

Oct. 11, 2022
It is largely known that oral drug delivery for macromolecules is often limited by the degradative environment of the gastrointestinal tract. Researchers from the Massachusetts Institute of Technology and their collaborators have presented Robocap, an oral mucus-clearing drug-delivery capsule that enhances the gastrointestinal absorption of drugs.
Read More
Oral medication

NMPA nod gives Hua Medicine first GKA approval in diabetes

Oct. 10, 2022
By Doris Yu
Hua Medicine Ltd. has received marketing approval from China's NMPA for its glucokinase activator (GKA), Huatangning (dorzagliatin tablets), for two indications: as a monotherapy to improve blood glucose control for drug-naïve type 2 diabetes patients and in combination with metformin in metformin-tolerated type 2 diabetes patients to control blood glucose level. It marks the first GKA drug to gain approval in any market, according to Hua.
Read More